MedTrace Logo

PREFERS (Preserved and Reduced Ejection Fraction Epidemiological Regional Study) Stockholm Heart Failure Study

NCT03671122 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 683

Last updated 2022-03-31

No results posted yet for this study

Summary

Heart failure (HF) with preserved (HFpEF) or reduced (HFrEF) ejection fraction is associated with poor prognosis and quality of life. While the incidence of HFrEF is declining and HF treatment is effective, HFpEF is increasing, with no established therapy. PREFERS Stockholm is an epidemiological study with the aim of improving clinical care and research in HF and to find new targets for drug treatment in HFpEF starting with a cardiac biopsy study in elective CABG patiens.

Conditions

  • Heart Failure, Diastolic
  • Heart Failure，Congestive

Interventions

DIAGNOSTIC_TEST

Cardiac imaging in the PREFERS and CABG PREFERS cohorts

performed at baseline and after 1 year

OTHER

Biomarker analysis in the PREFERS and CABG PREFERS chorts

blood samples will be taken for biomarker analysis at baseline and after 1 year

PROCEDURE

Cardiac biopsies in the CABG PREFERS cohort

myocardial biopsies from the right trium the left and right ventricles will be taken during elective CABG

Sponsors & Collaborators

  • The Swedish Research Council

    collaborator OTHER_GOV

  • Region Stockholm

    collaborator OTHER_GOV

  • Karolinska Institutet

    lead OTHER

Principal Investigators

  • Cecilia M Linde, MD PhD · Institution of Internal medicine, Karolinska University Hospital and Karolinska Institutet

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2021-01-31
Completion
2021-02-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03671122 on ClinicalTrials.gov